← All trials
NCT01188928
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2010
- Primary completion
- Mar 1, 2011
- Completion date
- Mar 1, 2011
- First posted
- —
- Last posted
- —
- Enrollment
- 1152
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Leo PharmaLead sponsor
- Henry Ford Health SystemOverall official - principal investigator
- University of PittsburghOverall official - principal investigator
- Dermatology Clinical Research Center of San AntonioOverall official - principal investigator
- Progressive Clinical ResearchOverall official - principal investigator
- Atlanta Dermatology, Vein & Research CenterOverall official - principal investigator
- Palm Beach Research CenterOverall official - principal investigator
- Burke Pharmaceutical ResearchOverall official - principal investigator
- Ameriderm ResearchOverall official - principal investigator
- Somerset Skin CentreOverall official - principal investigator
- Altman Dermatology AssociatesOverall official - principal investigator
- Peachtree Dermatology Associates Research CenterOverall official - principal investigator
- North Florida Dermatology AssociatesOverall official - principal investigator
- Dermatology Research Center, IncOverall official - principal investigator
- Gwinnett Clinical Research Center, IncOverall official - principal investigator
- Colorado Medical Research Center, Inc.Overall official - principal investigator
- Minnesota Clinical Study CenterOverall official - principal investigator
- Skin Surgery Medical Group, Inc.Overall official - principal investigator
- Indiana Clinical Trials CenterOverall official - principal investigator
- Dawes Fretzin Clinical Research GroupOverall official - principal investigator
- Karl G. Heine, M. D. DermatologyOverall official - principal investigator
- Hamzavi DermatologyOverall official - principal investigator
- Owensboro Dermatology AssociatesOverall official - principal investigator
- Oregon Dermatology and Research CenterOverall official - principal investigator
- Horizons Clinical Research Center, LLCOverall official - principal investigator
- David Fivenson, MD Dermatology, PLCOverall official - principal investigator
- Walter Nahm, MD, Ph.D., IncOverall official - principal investigator
- Grekin Skin InstituteOverall official - principal investigator
- The Dermatology Group, PCOverall official - principal investigator
- Great Lakes Research Group, IncOverall official - principal investigator
- King-Maceyko Dermatology AssociatesOverall official - principal investigator
- Triangle Medical Research Associates, LLCOverall official - principal investigator
- Derm Research Center of New YorkOverall official - principal investigator
- Clinical Trials of Texas, IncOverall official - principal investigator
- Anderson & Collins Clinical Research, Inc.Overall official - principal investigator
- Hudson DermatologyOverall official - principal investigator
- Horizon Research Group, Inc.Overall official - principal investigator
- Lawrence J. Green, MD, LLCOverall official - principal investigator
- Baylor UniversityOverall official - principal investigator
- Visions Clinical ResearchOverall official - principal investigator
- International Dermatology Research Inc.Overall official - principal investigator
- J&S Studies Inc.Overall official - principal investigator
- Premier Research GroupOverall official - principal investigator
- Torrance Clinical ResearchOverall official - principal investigator
- Advanced Clinical Research Inc.Overall official - principal investigator
- Deaconess ClinicOverall official - principal investigator
- Windsor DermatologyOverall official - principal investigator
- Icahn School of Medicine at Mount SinaiOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.